What one share of Cytokinetics, Incorporated holds
We are a biopharmaceutical company focused on discovering, developing and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.
Cytokinetics, Incorporated’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.54 |
|---|---|
| Profit | −$7.18 |
| Capex (buildings and equipment) | $0.20 |
| Free cash flow | −$4.67 |
| Cash and investments | $1.84 |
| Debt | $1.98 |
| Book value | −$1.25 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2009 | $8.44 | $2.54 | $0.06 | $0.81 | — | $10.60 |
| 2010 | $0.24 | −$4.61 | $0.05 | −$4.24 | — | $6.32 |
| 2011 | $0.34 | −$4.30 | $0.04 | −$3.90 | — | $3.86 |
| 2012 | $0.42 | −$2.30 | $0.01 | −$1.85 | — | $2.95 |
| 2013 | $1.12 | −$1.24 | $0.02 | −$0.30 | — | $1.77 |
| 2014 | $1.31 | −$0.41 | $0.03 | −$1.29 | — | $2.38 |
| 2015 | $0.74 | −$0.97 | $0.01 | $0.11 | — | $1.73 |
| 2016 | $2.50 | $0.39 | $0.04 | $0.83 | — | $2.32 |
| 2017 | $0.27 | −$2.59 | $0.06 | −$2.12 | — | $2.04 |
| 2018 | $0.58 | −$1.95 | $0.02 | −$1.88 | — | $0.47 |
| 2019 | $0.47 | −$2.11 | $0.05 | −$1.62 | — | −$0.18 |
| 2020 | $0.87 | −$1.97 | $0.17 | −$0.03 | — | $1.60 |
| 2021 | $0.92 | −$2.80 | $0.64 | −$2.49 | — | $2.88 |
| 2022 | $1.05 | −$4.33 | $0.13 | −$3.46 | — | −$1.14 |
| 2023 | $0.08 | −$5.45 | $0.01 | −$4.31 | — | −$3.80 |
| 2024 | $0.17 | −$5.26 | $0.03 | −$3.57 | — | −$1.15 |
| 2025 | $0.73 | −$6.54 | $0.21 | −$4.45 | — | −$5.37 |
Common questions about Cytokinetics, Incorporated
How much does one share of Cytokinetics, Incorporated earn?
Over the last 12 months, Cytokinetics, Incorporated lost $7.18 for each share on $0.54 of sales.
Does Cytokinetics, Incorporated pay a dividend?
Cytokinetics, Incorporated didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Cytokinetics, Incorporated’s book value per share?
Cytokinetics, Incorporated’s book value is negative (−$1.25 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Cytokinetics, Incorporated have?
Each share of Cytokinetics, Incorporated has $1.84 of cash and investments and $1.98 of debt, as of June 30, 2026.
What is Cytokinetics, Incorporated’s free cash flow per share?
−$4.67 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Cytokinetics, Incorporated bought back shares?
Cytokinetics, Incorporated’s share count rose about 1143% from 2009 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.